Simplify Logo

Full-Time

Scientist – Oligonucleotide Chemistry

Confirmed live in the last 24 hours

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Position is onsite in Cambridge, MA.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Chemistry or equivalent discipline with focus on nucleic acid chemistry with 5+ years of relevant experience.
  • Solid understanding of nucleoside/nucleotide/oligonucleotide chemistry and biology with an in-depth understanding of the commonly used modifications in oligonucleotide therapeutics.
  • Deep understanding of RNA structure and its interactions in biological systems, preferably with hands on experience running in vitro assays.
  • Must have hands on experience with the operation of low- and high-throughput oligonucleotide synthesis machinery (Mermade, Dr. Oligo) and routine laboratory instruments such as HPLC/UPLC, UV thermal melting, LCMS.
  • Strong communication skills in a variety of settings, ability to share and discuss scientific data clearly to peers and to senior leadership.
  • Proven track record in the field of oligonucleotide therapeutics (patents, publications, conference presentations, etc).
  • Team oriented and collaborative approach to work across multiple teams.
  • Attention to detail, critical analysis of data/reports, and troubleshooting abilities.
  • Proven ability to achieve results, keep projects on timeline, and find solutions as needed to ensure that project deliverables are met.
Responsibilities
  • Contribute to the development of Korro Bio’s proprietary medicinal chemistry platform.
  • Perform oligonucleotide solid phase synthesis and purification and delivery of high-quality oligonucleotides at low to mid scales for in vitro and in vivo studies.
  • Operate independently in the lab using all standard modern oligonucleotide synthesizers (Mermade, Dr. Oligo), purifiers (HPLC, Akta) and analysis (HPLC, LCMS).
  • Actively keep up to date with the ongoing research in the RNA therapeutics field and contribute to the development of proprietary designs and drafting of the patent applications.
  • Collaborate cross-functionally with Biology, Delivery, and In Vitro and In Vivo Pre-clinical Pharmacology teams to advance Korro Bio’s early research activities to preclinical development.
  • Independently run laboratory experiments to support and advance discovery efforts.
  • Multi-task across several projects and manage time effectively in a fast paces environment to achieve results.
  • Design and write protocols, perform experiments, organize and analyze data, interpret results, record experiments in an electronic lab notebook, and summarize work in presentations and technical reports.
  • Adhere to all laboratory safety requirements and standard operating procedures, help maintaining general laboratory functionality, including lab equipment maintenance and the ordering, and receiving of lab supplies.
  • Other duties as assigned.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes in protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to advance RNA editing technology to provide new treatment options for patients suffering from debilitating diseases.

Company Stage

IPO

Total Funding

$451.5M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

4%

1 year growth

0%

2 year growth

17%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $70 million raised for clinical trials and growth positions Korro Bio to advance its pipeline and achieve significant milestones.
  • The appointment of industry veterans like Dr. Rachel Meyers and Tim Pearson to the board strengthens the company's leadership and strategic direction.
  • Korro Bio's stock price surge of 171% in November indicates strong market confidence and potential for high returns.

What critics are saying

  • The biopharmaceutical market is highly competitive, and Korro Bio must continuously innovate to maintain its edge.
  • The success of RNA editing therapies is still uncertain and hinges on successful clinical trials and regulatory approvals.

What makes Korro Bio unique

  • Korro Bio's focus on RNA editing allows for precise single base modifications, offering a potentially safer and more accurate alternative to traditional gene editing and gene therapy.
  • The company's strategy of leveraging machine learning to enhance RNA delivery and platform development sets it apart from competitors.
  • Korro Bio's recent $70 million private placement and merger with Frequency Therapeutics provide substantial financial backing and expanded capabilities.

Help us improve and share your feedback! Did you find this helpful?